Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The primary hypothesis is that INT-747 will cause a reduction in alkaline phosphatase levels
in Primary Biliary Cirrhosis patients, over a 12 week treatment period, as compared to
placebo.